glp 1 neurodegenerative disease Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine Repurposing GLP1 agonists for neurodegenerative
Description
Other factors especially costs, as well as concerns about long-term safety and side effects, and a preference for other weight-loss tactics have undoubtedly played a role, based on patient surveys
Exploring more GLP-1R derivatives and other analogs for islet transplantation has become necessary
Despite the abundance of GLP-1 research, studies in UC have been less consistent, especially body weight
Further evidence has increased the understanding of GIP showing that GIP likely still has a role in diabetes despite normal or sometimes elevated concentrations
